Table 1.
| Characteristic | Normal weight (n = 678) | Overweight (n = 712) | Obese (n = 391) | P for trend |
|---|---|---|---|---|
| Median age at randomization | <.001 | |||
| Years (IQR) | 54 (50–62) | 59 (52–65) | 61 (53–66) | |
| History of cardiovascular disease | <.001 | |||
| Yes | 147 (22) | 253 (36) | 204 (52) | |
| Smoking history | .89 | |||
| Nonsmoker | 311 (47) | 342 (49) | 182 (47) | |
| Previous or current smoker | 348 (53) | 357 (51) | 203 (53) | |
| Tumor stage | .02 | |||
| pT1 | 330 (49) | 306 (43) | 159 (41) | |
| pT2 | 289 (43) | 355 (50) | 196 (50) | |
| pT3/4 | 57 (8) | 51 (7) | 36 (9) | |
| Nodal status | .98 | |||
| Negative | 218 (32) | 237 (33) | 125 (32) | |
| Positive | 460 (68) | 475 (67) | 266 (68) | |
| Histologic grade | .56 | |||
| Grade I | 122 (19) | 113 (16) | 68 (18) | |
| Grade II | 326 (50) | 367 (53) | 197 (53) | |
| Grade III | 211 (32) | 217 (31) | 106 (29) | |
| Hormone receptor status | .79 | |||
| ER and PR positive | 517 (76) | 521 (73) | 298 (76) | |
| ER or PR positive | 161 (24) | 191 (27) | 93 (24) | |
| HER2 status | .79 | |||
| Positive | 15 (2) | 20 (3) | 9 (3) | |
| Negative | 618 (98) | 635 (97) | 349 (98) | |
| Histology | .71 | |||
| Lobular | 135 (20) | 104 (15) | 87 (22) | |
| Other | 543 (80) | 608 (85) | 304 (78) | |
| Breast-conserving surgery | .63 | |||
| Yes | 331 (49) | 351 (49) | 197 (50) | |
| Prior (neo)adjuvant chemotherapy | .002 | |||
| Yes | 485 (72) | 478 (67) | 245 (63) | |
| Median previous duration of tamoxifen | .38 | |||
| Years (IQR) | 2.3 (2.1–2.5) | 2.3 (2.1–2.5) | 2.3 (2.1–2.5) | |
| Recommended treatment duration of anastrozole | .70 | |||
| 3 years | 337 (50) | 344 (48) | 201 (51) | |
| 6 years | 341 (50) | 368 (52) | 190 (49) |
a
Percentages may exceed 100% because of rounding. ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; IQR = interquartile range; PR = progesterone receptor.
b
Missing values: smoking history (n = 38), tumor status (n = 2), histologic grade (n = 54), and HER2 status (n = 135).